Clinical strategies with antibody-drug conjugates as potential modifications for virotherapy.

Autor: Liao ZX; Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 80424, Taiwan., Huang PH; Department of Oncology, National Taiwan University Hospital, Taipei 10051, Taiwan., Hsu SH; Institute of Polymer Science and Engineering, National Taiwan University, Taipei 10051, Taiwan., Chang HH; Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan., Chang CH; School of Pharmacy, National Cheng Kung University, Tainan, 70101, Taiwan., Tseng SJ; Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan; NCKU Center of Applied Nanomedicine, Tainan 70101, Taiwan. Electronic address: z11302016@ncku.edu.tw.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2024 Nov; Vol. 29 (11), pp. 104165. Date of Electronic Publication: 2024 Sep 11.
DOI: 10.1016/j.drudis.2024.104165
Abstrakt: The ability to selectively target cancer cells makes antibody-drug conjugates (ADCs) promising therapeutic options. They have been tested in clinical trials as a vehicle for tumor-specific delivery of cytotoxic payloads for a range of cancers. However, systemic administration of oncolytic virotherapy is challenging, because only a small portion of injected viruses reach the target. Despite the approval of higher viral doses, most viruses still end up in the liver, potentially causing toxicity in that organ. Integrating ADCs with virotherapy in the form of antibody-virus conjugates or virus-drug conjugates can potentially overcome these challenges and improve therapeutic outcomes.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: